Teva Pharmaceutical Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
For the full year, sales was USD 14,925 million compared to USD 15,878 million a year ago. Net loss was USD 2,353 million compared to net income of USD 417 million a year ago. Basic loss per share from continuing operations was USD 2.12 compared to basic earnings per share from continuing operations of USD 0.38 a year ago. Diluted loss per share from continuing operations was USD 2.12 compared to diluted earnings per share from continuing operations of USD 0.38 a year ago.